Therapeutic targeting of MAP2K1 in the MAPK pathway was a promising strategy for EGFR inhibitor (erlotinib)-resistant HNSCC patients (Jain et al., 2019). The gene discussed is MAP2K1; the disease is head and neck squamous cell carcinoma.